Regeneron Pharmaceuticals (NASDAQ:REGN) is a leading biotechnology company headquartered in Tarrytown, New York. Since its founding in 1988 by Dr. Leonard S. Schleifer and Dr. George D. Yancopoulos, the firm has focused on discovering, developing, and commercializing novel medicines for serious medical conditions. Drawing on its integrated research and development model, Regeneron combines genetic insights with proprietary technology platforms to advance therapeutic candidates from early discovery through regulatory approval.
The company’s portfolio includes EYLEA, an anti-VEGF therapy for wet age-related macular degeneration and other eye diseases; Dupixent, an anti-IL-4 receptor alpha antibody approved for atopic dermatitis, asthma and related conditions; and Libtayo, a PD-1 inhibitor indicated for certain skin and lung cancers. In collaboration with Sanofi, Regeneron has also brought forward treatments such as Praluent for hypercholesterolemia and Kevzara for rheumatoid arthritis. During the COVID-19 pandemic, Regeneron developed a monoclonal antibody cocktail, REGEN-COV, which received emergency use authorization for post-exposure prophylaxis and treatment in high-risk patients.
Regeneron’s research engine is built on its VelociSuite technology, which includes VelociGene and VelocImmune platforms designed to accelerate target identification and antibody generation. This approach has enabled the company to build a robust pipeline spanning immuno-oncology, metabolic and ophthalmic disorders, as well as rare diseases. Regeneron continues to invest in translational science to explore new targets and refine personalized medicine strategies.
With a global footprint spanning North America, Europe, Asia and beyond, Regeneron collaborates with academic institutions, government agencies and industry partners. Under the leadership of Dr. Schleifer as CEO and President and Dr. Yancopoulos as President and Chief Scientific Officer, the company remains committed to delivering innovative therapies that address unmet medical needs worldwide.
